Efficacy of paclitaxel-eluting stent implantation in hemodialysis patients

Michiaki Higashitani1, Fumiaki Mori, Norihiro Yamada

  • 1Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 160-0022, Japan. mhigasit@hij.twmu.ac.jp

Heart and Vessels
|January 27, 2011
PubMed

Insights

Paclitaxel-eluting stents (PES) show improved outcomes for hemodialysis patients compared to sirolimus-eluting stents (SES). PES significantly reduced restenosis and target lesion revascularization rates in this high-risk group.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Nephrology

Background:

  • Hemodialysis patients are a high-risk group for restenosis after percutaneous coronary intervention (PCI).
  • Sirolimus-eluting stents (SES) have shown limited efficacy in reducing restenosis and target lesion revascularization (TLR) in this population.
  • Paclitaxel-eluting stents (PES) are a potential alternative for improving outcomes.

Purpose of the Study:

  • To compare the efficacy of paclitaxel-eluting stents (PES) versus sirolimus-eluting stents (SES) in reducing restenosis and TLR in hemodialysis patients.
  • To investigate angiographic outcomes in hemodialysis patients treated with PES compared to SES.

Main Methods:

  • Retrospective cohort study analyzing 54 hemodialysis patients (87 lesions) with PES and 49 patients (68 lesions) with SES.
  • Angiographic follow-up obtained at 8-10 months for a subset of lesions in both groups.
  • Baseline characteristics, including peripheral artery disease, were compared between groups.

Main Results:

  • The PES group had a higher prevalence of peripheral artery disease at baseline.
  • Binary restenosis rates were significantly lower in the PES group (13.6%) compared to the SES group (39.5%) (p=0.034).
  • Target lesion revascularization (TLR) rates were also significantly lower in the PES group (9.3%) versus the SES group (26.5%) (p=0.041).

Conclusions:

  • Paclitaxel-eluting stents (PES) are more effective than sirolimus-eluting stents (SES) in reducing restenosis and target lesion revascularization (TLR) in hemodialysis patients.
  • PES may offer improved angiographic outcomes for this specific high-risk patient cohort.

Related Concept Videos

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Peritoneal Dialysis III: Nursing Management01:25

Peritoneal Dialysis III: Nursing Management

Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this measurement...